Metagenomi Therapeutics, Inc. Contract Liability (Deferred Revenue)
Metagenomi Therapeutics, Inc. (MGX) had Contract Liability (Deferred Revenue) of $11.20 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-10
- 2026-06-30: Contract with Customer, Liability, Current $11.20M.
- 2026-03-31: Contract with Customer, Liability, Current $9.31M.
- 2025-12-31: Contract with Customer, Liability, Current $8.70M.
- 2025-09-30: Contract with Customer, Liability, Current $12.90M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $11.20M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $9.31M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $8.70M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $12.90M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $18.94M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $25.50M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $22.76M 10-K · filed 2026-03-05 |
| 2024-09-30 | $29.05M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $32.98M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $48.29M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $48.07M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |